• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Visioneering Tech touts NaturalVue contact lens pediatric myopia study

Visioneering Tech touts NaturalVue contact lens pediatric myopia study

November 8, 2018 By Fink Densford

Visioneering Technologies

Visioneering Technologies Inc yesterday released results from a pediatric study of its NaturalView multifocal contact lens intended to treat myopia, touting

Results from the trial were presented by study lead Dr. Thomas Aller of the UC Berkeley School of Optometry at the American Academy of Optometry Conference in San Antonio this week.

In the trial, investigators examined changes in vision and eye shape in myopic children wearing the NaturalVue multifocal contacts, with 24 children completing a six-month follow up and 19 completing 12 months. The average age in the study was 10.8 years old, the Atlanta-based company said.

Prior to wearing the NaturalVue lenses, children experienced worsening myopic vision by 1.28 ± 0.79 diopters per year, Visioneering Tech said. For the year the children wore  the NaturalVue multifocal lens, the rate was reduced to 0.24 diopters per year, a decrease of 1.04 diopters per year, or an 81% reduction in the rate of progression.

Data from the trial also indicated that the lenses reduced changes in eye shape in the patients, reducing from an average predicted increase in axial length of 0.43 ± 0.26 mm in the year prior to wearing the lenses to 0.20 ± 0.19 mm in the year while wearing them, Visioneering Tech said.

“The prevalence of myopia is increasing among children globally at alarming rates, and identifying better ways to manage myopia has become a top priority for vision care experts worldwide. The NaturalVue Multifocal data are very encouraging based on the level of decrease in changes in both refractive error and expected axial length growth, especially in a group of very fast progressing myopic children. To achieve more than 1.00 diopters of decrease in myopic refractive error change on a prospective basis after one year is quite remarkable and promising. The unique design of NaturalVue Multifocal offers intervention for multiple potential causes of myopic progression, and its availability as a daily disposable contact lens makes it ideal for use in children. I am excited to continue this research and follow these children into their second year of wear,” Dr. Aller  said in a press release.

Last March, Visioneering Tech said that it closed a $25.5 million (AUD $33.3 million) initial public offering in Australia, with funds going to support its NaturalVue multifocal contact lenses.

Filed Under: Clinical Trials, Optical/Ophthalmic Tagged With: Visioneering Technologies

More recent news

  • Preceptis Medical has a new CEO as it advances ear tube tech
  • FDA clears first over-the-counter cuffless blood pressure monitor
  • Mendaera wins FDA clearance for robotic needle placement
  • Johnson & Johnson seeks to have $442 million antitrust verdict tossed out
  • Former Masimo COO is joining BD to run Connected Care

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy